Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00419796
First received: January 8, 2007
Last updated: November 28, 2007
Last verified: November 2007
  Purpose

This randomized study will compare the effect of lumiracoxib, ibuprofen and placebo on 24-hour blood pressure profile and on urinary excretions of eicosanoids in controlled hypertensive patients who have osteoarthritis.


Condition Intervention Phase
Osteoarthritis With Controlled Hypertension
Drug: Lumiracoxib
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A 4-Week, Multicentre, Randomized, Double-Blind, Placebo Controlled, Double Dummy, Parallel Group Study, to Assess the Effect of Lumiracoxib 100 mg o.d. and Ibuprofen 600 mg t.i.d on 24-Hour Blood Pressure Profile and on Urinary Excretions of Eicosanoids, in Osteoarthritis Patients With Controlled Hypertension

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change from baseline in average 24-hour systolic blood pressure (BP) derived from ambulatory blood pressure monitoring (ABPM) after 4 weeks of treatment
  • Urinary eicosanoid excretion

Secondary Outcome Measures:
  • Change from baseline in average 24-hour diastolic BP derived from ABPM after 4 weeks of treatment
  • Day and night time blood pressure (systolic and diastolic) derived from ABPM after 4 weeks of treatment
  • Pharmacokinetics

Estimated Enrollment: 78
Study Start Date: November 2006
Study Completion Date: September 2007
  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female outpatients of at least 50 years of age.
  • Female patients must be either post-menopausal for one year, surgically sterile, or using effective contraceptive methods such as barrier method with spermicide or intra-uterine device. Oral contraceptives use is not allowed 4 weeks prior screening and throughout the duration of the study. Patients on hormonal replacement therapy are allowed if they have been on a stable dose for at least 6 months.
  • Primary osteoarthritis of the hand, hip or knee according to American College of Rheumatology (ACR) criteria or osteoarthritis of the spine. One joint will be identified as the target joint and will be evaluated throughout the duration of the trial.
  • Is expected to need non-steroidal anti-inflammatory drugs (NSAID) or simple analgesic therapy for osteoarthritis for at least the next 6 weeks.
  • Controlled hypertension with mean sitting systolic blood pressure (MSSBP) <140 mmHg and mean sitting diastolic blood pressure (MSDBP) <90 mmHg (mean of 3 cuff blood pressure measurements). Patients must have taken the same fixed dose of antihypertensive medication(s) on a regular basis for at least 3 consecutive months prior to screening and are not expected to adjust their antihypertensive medication(s) during the study. Regular wake-up times which are expected to continue for the duration of the trial.

Exclusion Criteria:

  • History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures.
  • Patients who have any known allergic-type reactions after taking acetylsalicylic acid or NSAIDs which may include (but are not limited to) history of asthma, acute rhinitis, nasal polyps, angioneurotic edema, urticaria or other allergic-type reactions
  • History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/ml).
  • History of cardiac and cerebral thrombotic/ ischemic diseases and/ or events as listed below:

angina pectoris (of any severity) or other evidence of coronary heart disease; myocardial infarction; coronary heart disease with ECG-evidence of silent myocardial infarction; coronary artery bypass grafting (CABG) or percutaneous coronary intervention (any PCI procedure); clinically significant carotid artery stenosis or history of carotid endarterectomy; congestive heart failure, NYHA class II - IV; second or third degree heart block in the absence of permanent pacing and all potentially life-threatening arrhythmia or symptomatic arrhythmia; clinically significant valvular heart disease; cerebrovascular disease; peripheral arterial disease

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00419796

Locations
United States, New Jersey
Novartis
East Hanover, New Jersey, United States, 07936-1080
Sponsors and Collaborators
Novartis
Investigators
Principal Investigator: Novartis Investigator site
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00419796     History of Changes
Other Study ID Numbers: CCOX189A2475
Study First Received: January 8, 2007
Last Updated: November 28, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
Osteoarthritis, controlled hypertension, lumiracoxib, ibuprofen, high blood pressure

Additional relevant MeSH terms:
Hypertension
Osteoarthritis
Vascular Diseases
Cardiovascular Diseases
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Ibuprofen
Lumiracoxib
Diclofenac
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents
Cyclooxygenase 2 Inhibitors

ClinicalTrials.gov processed this record on April 22, 2014